VRTX Overview
Upcoming Projects (VRTX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (VRTX)
-
Don’t see a project related to the company you care about? Create your own!
Expired Projects (VRTX)
-
Analyzing Recent Developments in Induced Pluripotent Stem Cell Therapy
Tickers: PSTI, VRTX, Healios KK, 4593:Tokyo
Execute By: Nov 30, 2021
Upcoming & Overdue Catalysts (VRTX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (VRTX)
-
Vertex plans to submit a New Drug Application (NDA) to the FDA for VX-661 in combination with ivacaftor in the second half of 2017
Ticker: VRTX
Occurred on: Aug 24, 2017 -
Phase I safety data on VX-152 / VX-440 expected in second half of 2017
Ticker: VRTX
Occurred on: Jul 18, 2017 -
VX-152, VX-440 "triplet" potential Phase II efficacy data in hetero CF expected in early 2017
Ticker: VRTX
Occurred on: Jul 18, 2017 -
Phase 3 data of VX-661 in patients with two Copies of the F508del mutation are expected by early 2017
Ticker: VRTX
Occurred on: Mar 28, 2017 -
Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis
Tickers: VRTX, CNCE
Occurred on: Mar 06, 2017 -
Enrollment in VX-661 in combination with ivacaftor in people with gating mutations is expected to complete in late 2016 or early 2017
Ticker: VRTX
Occurred on: Jan 08, 2017 -
Vertex (VRTX) Announces Phase 3 Results Evaluating ORKAMBI in Children 6-11 with Cystic Fibrosis with Two Copies of F508del Mutation
Ticker: VRTX
Occurred on: Nov 07, 2016 -
The FDA set a target review date of September 30, 2016 for a decision on Orkambi sNDA in Homozygous patients aged 6-11
Ticker: VRTX
Occurred on: Sep 28, 2016 -
FDA rejects Vertex's application for expanded use of KALYDECO
Ticker: VRTX
Occurred on: Feb 05, 2016
Strategic Initiatives (VRTX)
-
Vertex (VRTX) and Merck KgaA (MKGAY) Announce Collaboration and License Agreement Covering Four Oncology R&D Programs
Tickers: MRK, VRTX, MKGAY
Announcement Date: Jan 11, 2017 -
Vertex Pharmaceuticals (VRTX) Expands Agreement with Cystic Fibrosis Foundation Therapeutics (CFFT)
Ticker: VRTX
Announcement Date: Oct 14, 2016 -
Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics for Cystic Fibrosis
Tickers: VRTX, Moderna
Announcement Date: Jul 06, 2016